Evidence map›Paper›PMID 36409151›Full record

ReviewBrain pathology (Zurich, Switzerland)2023

The fate of interneurons, GABA

Afia B Ali, Anam Islam, Andrew Constanti

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain pathology (Zurich, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. The role of GABANeuroscience and biobehavioral reviews · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Decoding the mechanisms of amyloid-β in synaptic toxicity.Journal of Alzheimer's disease : JAD · 2026
    Review
  11. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
  12. Article
  13. Article
  14. ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?International journal of molecular sciences · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Afia B AliUCL School of Pharmacy, London, UK.ORCID 0000-0001-5203-5609
Anam IslamUCL School of Pharmacy, London, UK.
Andrew ConstantiUCL School of Pharmacy, London, UK.
The London College · GB

Funding

Alzheimer's Research UKRI ARUK-NC2020-UCLMedical Research Council UK GO501263Medical Research Council UKRI MR/N013867/1Wellcome Trust
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common neurological disease, which is associated with gradual memory loss and correlated with synaptic hyperactivity and abnormal oscillatory rhythmic brain activity that precedes phenotypic alterations and is partly responsible for the spread of the disease pathology. Synaptic hyperactivity is thought to be because of alteration in the homeostasis of phasic and tonic synaptic inhibition, which is orchestrated by the GABA

Indexed as

Alzheimer DiseaseInterneuronsReceptors, GABA-AExtracellular Matrixgamma-Aminobutyric AcidHumansgamma-Aminobutyric AcidReceptors, GABA-AAlzheimer's diseaseGABAinterneuronsneurodegenerationperineuronal netsSynaptic

Identifiers

PMID36409151
PMCPMC9836378
OpenAlexW4309511328

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.